Evidence map›Paper›PMID 32709481›Full record

ArticleJournal of autoimmunity2020

Type I IFN signaling in T regulatory cells modulates chemokine production and myeloid derived suppressor cells trafficking during EAE.

Shalini Tanwar, Cihan Oguz, Amina Metidji, Eric Dahlstrom, Kent Barbian, Kishore Kanakabandi, Lydia Sykora, Ethan M Shevach

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of autoimmunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Shalini TanwarCellular Immunology, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
Cihan OguzNCBR (NIAID Collaborative Bioinformatics Resource), Bethesda, MD, 20892, USA; Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, MD, 21701, USA.
Amina MetidjiCellular Immunology, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
Eric DahlstromGenomics Unit, Research Technologies Branch, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, MT, 59840, USA.
Kent BarbianGenomics Unit, Research Technologies Branch, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, MT, 59840, USA.
Kishore KanakabandiGenomics Unit, Research Technologies Branch, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, MT, 59840, USA.
Lydia SykoraGenomics Unit, Research Technologies Branch, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, MT, 59840, USA.
Ethan M ShevachCellular Immunology, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA. Electronic address: eshevach@niaid.nih.gov.
National Institutes of Health · USFrederick National Laboratory for Cancer Research · USNational Institute of Allergy and Infectious Diseases · US

Funding

RECEPTORS, CORECEPTORS, AND COUNTER RECEPTORS IN T CELL ACTIVATIONZ01AI000224 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI SHEVACH, ETHAN M. · 1985 to 2008
$3.5M
Intramural NIH HHS Z01 AI000224
6 · The paper itself

Abstract

Interferon-β has therapeutic efficacy in Multiple Sclerosis by reducing disease exacerbations and delaying relapses. Previous studies have suggested that the effects of type I IFN in Experimental Autoimmune Encephalomyelitis (EAE) in mice were targeted to myeloid cells. We used mice with a conditional deletion (cKO) of the type I IFN receptor (IFNAR) in T regulatory (Treg) cells to dissect the role of IFN signaling on Tregs. cKO mice developed severe EAE with an earlier onset than control mice. Although Treg cells from cKO mice were more activated, the activation status and effector cytokine production of CD4

Indexed as

AnimalsChemokine CCL22Chemokine CCL8Chemokines, CCEncephalomyelitis, Autoimmune, ExperimentalHumansInterferon Type ILymph NodesMacrophage Inflammatory ProteinsMiceMice, KnockoutMultiple SclerosisMyeloid-Derived Suppressor CellsReceptor, Interferon alpha-betaSignal TransductionT-Lymphocytes, RegulatoryCcl22 protein, mouseCcl8 protein, mouseCcl9 protein, mouseChemokine CCL22Chemokine CCL8Chemokines, CCInterferon Type IMacrophage Inflammatory ProteinsReceptor, Interferon alpha-betaChemokinesExperimental autoimmune encephalomyelitisMyeloid derived suppressor cellsRegulatory T cellsType 1 IFN Receptor-α

Identifiers

PMID32709481
PMCPMC7712497
OpenAlexW3043991706

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.